SCHEDULE 13G: Capital World Investors Discloses 5.6% Stake in Allogene Therapeutics

Capital World Investors has filed a Schedule 13G, reporting a 5.6% beneficial ownership stake in Allogene Therapeutics, Inc. as of March 31, 2025.

Summary

• Capital World Investors (CWI) reported beneficial ownership of 12,265,330 shares of Allogene Therapeutics, Inc. Common Stock.
• This ownership represents 5.6% of the 217,264,738 shares of Common Stock believed to be outstanding.
• CWI, a division of Capital Research and Management Company, holds sole voting power and sole dispositive power over all 12,265,330 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Allogene Therapeutics.
• SMALLCAP World Fund, Inc. is identified as a person known to have the right to receive or direct the receipt of dividends from, or the proceeds from the sale of, these securities.

Sentiment

Score: 5

Explanation: Neutral. A Schedule 13G is a factual disclosure of ownership and does not inherently convey positive or negative sentiment about the company's performance, though a significant institutional stake can be viewed as a positive signal by the market.

Positives

• Capital World Investors, a prominent institutional investor, has disclosed a significant 5.6% stake in Allogene Therapeutics, which could be interpreted by the market as a vote of confidence in the company's long-term prospects.

Risks

• No specific risks related to the issuer's operations or financial health are disclosed in this beneficial ownership report, as it primarily focuses on ownership disclosure.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in Allogene Therapeutics, a biotechnology company. Such investments can signal investor confidence in the company's long-term prospects within the competitive biotechnology and pharmaceutical sectors, particularly for companies focused on innovative therapies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Capital World Investors may be viewed positively, potentially signaling confidence in the company's long-term value and attracting further investor interest.

Key Dates

Keywords

Allogene Therapeutics, Capital World Investors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals, Investment Adviser